New ISPOR & ASCO data on home cancer care and patient experience
Insights from European patients and UK private oncology homecare to support your practice.
Across 2026, Sciensus is presenting new evidence at ISPOR and ASCO that focuses on three familiar pressures in oncology: closing evidence gaps in complex conditions, improving patient experience through home based treatment, and using digital and AI tools to scale care while capturing richer real world data.
Taken together, these studies are informing how Sciensus designs and delivers home oncology services, with the aim of setting a new standard of safe, patient-centred cancer care at home that aligns with the needs of consultants and their patients.
What’s new at ISPOR 2026
At ISPOR, Sciensus is sharing three studies on rare and complex conditions with direct relevance to oncology practice and service design.
- A multinational, patient centred survey framework in rare diseases, developed with Disc Medicine, shows a scalable way to generate high quality, generalisable data across dispersed patient populations and has been selected for the new Rare Disease Poster Tour.
- A multi country study with Rare Patient Voice (Konovo) maps where treatment access and support are breaking down across Europe, highlighting opportunities to design services that reduce burden and improve real world outcomes for people living with rare diseases, including those requiring systemic anti cancer therapies.
- An AI enabled ambient speech capture pilot (CareTranscribe) in home based care evaluates how digital documentation can reduce administrative burden, improve data capture in the home and surface contextual insights such as adherence barriers, education needs and day to day treatment challenges.
Insights from these studies are being fed back into Sciensus’ homecare models, supporting more structured, data driven approaches to patient assessment, communication and ongoing monitoring in the home setting.
Oncology-specific insights at ASCO 2026
Two ASCO abstracts focus squarely on cancer care access, home delivery and the experiences of patients receiving oncology treatment at home.
- A five country European study, run with Rare Patient Voice (Konovo), documents patient reported barriers to treatment access and home delivery in cancer care, including fragmented pathways and inconsistent availability of home services that impact continuity of care and overall experience.
- A UK based survey of privately funded patients explores their experience of home based oncology care, capturing satisfaction levels, perceived value and practical recommendations from patients on how to optimise homecare service delivery and quality.
These findings are directly shaping how Sciensus structures oncology homecare pathways, from referral and onboarding through to ongoing support, with the goal of defining a consistent, high quality standard of home cancer care that reflects what patients say matters most.
How this connects to UK private practice
For UK private oncologists, these data offer several practical take aways: a clearer picture of where patients still experience barriers to accessing treatment and home delivery evidence that well-designed homecare models can reduce burden while maintaining strong clinical governance and early indications that AI enabled documentation may help free up clinician time while strengthening real world evidence capture in patients’ homes.
By embedding these insights into service design, Sciensus is working towards a new standard of connected, evidence-based cancer care at home that complements clinic based treatment and supports better outcomes and experience.
